Introduction: HBV mutations, including A1762T/G1764A, C1653T, T1753V, and T1674G/C, in the core promoter (CP) region of the viral genome are typically the ones that increase the risk of HCC.
Comprehensive Analysis of Clinically Significant Hepatitis B Virus Mutations in Relation to Genotype, Subgenotype and Geographic Region.
Abstract: HCC-associated mutations were detected in 33.7% of the sequences, with significantly higher frequency of C1653T, T1753V and A1762T/G1764A in genotype G than C (P < 0.001).
Result: C1653T, T1753V and A1762T/G1764A were highly frequent in genotype G (95, 95, and 97.5%, respectively), followed by genotype C (12, 18.1, and 46.1%, respectively), while Pre-S deletions prevailed in genotype C (3.3%) (Table 1).
Result: The frequencies of C1653T, T1753V and A1762T/ PMID: 32568442
2020
Journal of viral hepatitis
Abstract: rs3135395-T, rs477515-T and rs2395178-G were inversely associated with the generation of A1762T/G1764A, T1753V and C1653T, the HCC-risk HBV mutations.
High possibility of hepatocarcinogenesis in HBV genotype C1 infected Cambodians is indicated by 340 HBV C1 full-genomes analysis from GenBank.
Abstract: Multiple mutations were confirmed in 24 Cambodian C1 isolates, especially double mutation at A1762T/G1764A in 18 isolates (75.0%), and combination mutation at C1653T and/or T1753V and A1762T/G1764A in 14 isolates (58.3%).
Introduction: Mutations at C1653T and/or T1753V and A1762T/G1764A in Enhancer II/basal core promoter were also reported to be associated with HCC in 1999 compared with other liver disease statuses.
Introduction: The c
Next generation sequencing identifies baseline viral mutants associated with treatment response to pegylated interferon in HBeAg-positive chronic hepatitis B.
Abstract: Based on NGS, the prevalence of T1753V (T1753C/A/G) and A1762T/G1764A variants were significantly lower in responders compared to non-responders (8.3% vs.
Abstract: The absence of T1753V and A1762T/G1764A mutations were factors associated with CR (OR 11.65, 95%CI 1.36-100.16, P = 0.025, and OR 4.36, 95%CI 1.08-17.63, P = 0.039, respectively).
Abstract: The existence of pre-treatment T1753V, A1762T/G1764A mutations and their combination yielded negative predictive values of 94.7%, 85.7% and 93.8%, respectively.
Locus 5p13.1 may be associated with the selection of cancer-related HBV core promoter mutations.
PMID: 31341412
2019
International journal of medical sciences
Introduction: The precore mutation (G1896A), mutations in enhancer II (C1653T) and the BCP (T1753V and the double mutations, A1762T, G1764A), and deletions in the pre-S region have been reported to be associated with the development of HCC.
Analysis of hepatitis B virus genotype and gene mutation in patients with advanced liver disease in East Kalimantan, Indonesia.
Abstract: The C1505A mutation in X region, T1753V and A1762T/G1764A mutations in the basal core promoter region and C1858T in precore (PC) region were frequent and only detected in patients with ALD (28.9, 40, 73.5 and 17.6%, respectively), whereas the G1896A mutation in the PC region was frequently detected in HBV carriers.
The mutation of hepatitis B virus and the prognosis of hepatocellular carcinoma after surgery: a pilot study.
PMID: 29628773
2018
Cancer management and research
Introduction: Other BCP mutations, notably T1753V and T1768A, have also been reported to be associated with an increased risk of HCC.
Introduction: The X gene mutations (two of the most common being C1653T and T1753V) and Pre S2 gene deletions have been associated with increased incidence of HCC.
Analysis of HBV basal core promoter/precore gene variability in patients with HBV drug resistance and HIV co-infection in Northwest Ethiopia.
Discussion: As the result of BCP polymorphism, clinically important multiple mutations per a study subject; such as T1753V/A1762T/G1764A and A1762T/G1764A/C1766T (or T1768A) were also the characteristics of the current study.
Discussion: mutations which were absent in the current study, TA1 to TA3 rich BCP mutations such as A1752C/G/T (8.4%), T1753V (18.9%), A1762T (28.7%), G1764A (35.0%) and T1773C (37.1%) we
Patients with Coexistence of Circulating Hepatitis B Surface Antigen and Its Antibody May Have a Strong Predisposition to Virus Reactivation During Immunosuppressive Therapy: A Hypothesis.
Abstract: DNA sequencing analysis of the HBV genome revealed triple mutations (A1762T, G1764A, and T1753V) in the BCP region, which could further enhance the ability of HBV replication.
Introduction: Recently, a meta-analysis showed a statistically significant summary odds ratios (OR) of HCC obtained for A1762T/G1764A (3.79, 95% CI=2.71 to 5.29) and T1753V (2.35, 95% CI=1.63 to 3.40) in the BCP region.
Introduction: Site-directed mutagenesis (A1762T, G1764A, and T1753V) of the wild-type clone exhibited appreciably stronger replica
HBV mutation literature information.
PMID: 
2022
Frontiers in oncology
Browser Board
Co-occurred Entities
Filtrator
ViMRT